One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
In vivo imaging of chronic active lesions in multiple sclerosis
Alberto Calvi, Lukas Haider, Ferran Prados, Carmen Tur, Declan Chard, Frederik Barkhof
doi : 10.1177/1352458520958589
Volume 28 Issue 5, April 2022
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes�
Leoni Rolfes, Sven G Meuth
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO
Zoé LE van Kempen, Laura Hogenboom, Joep Killestein
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—Commentary
Daniel Gratch, Lana Zhovtis Ryerson
Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matter
Samuel Klistorner, Michael H Barnett, Con Yiannikas, Joshua Barton, John Parratt, Yuyi You, Stuart L Graham, Alexander Klistorner
Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder
Fenglian Zheng*, Yuxin Li*, Zhizheng Zhuo, Yunyun Duan, Guanmei Cao, Decai Tian, Xinghu Zhang, Kuncheng Li, Fuqing Zhou, Muhua Huang, Haiqing Li, Yong
Cortical involvement and leptomeningeal inflammation in myelin oligodendrocyte glycoprotein antibody disease: A three-dimensional fluid-attenuated inversion recovery MRI study
Dimitrios Tzanetakos, John S Tzartos, Aigli G Vakrakou, Marianthi Breza, Georgios Velonakis, Panos Stathopoulos, Eirini Pantou, Ioannis Markakis, Dimi
White matter microstructural differences in children and genetic risk for multiple sclerosis: A population-based study
C Louk de Mol, Rinze F Neuteboom, Philip R Jansen, Tonya White
Functional and structural MRI correlates of executive functions in multiple sclerosis
Olga Marchesi, Raffaello Bonacchi, Paola Valsasina, Paolo Preziosa, Elisabetta Pagani, Laura Cacciaguerra, Alessandro Meani, Lorenzo Conti, Damiano Mi
Impaired motion perception is associated with functional and structural visual pathway damage in multiple sclerosis and neuromyelitis optica spectrum disorders
Noah Ayadi, Frederike C Oertel, Susanna Asseyer, Rebekka Rust, Ankelien Duchow, Joseph Kuchling, Judith Bellmann-Strobl, Klemens Ruprecht, Alexander K
Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients
Marco Pitteri*, Roberta Magliozzi*, Richard Nicholas*, Stefano Ziccardi, Anna Isabella Pisani, Francesco Pezzini, Damiano Marastoni, Massimiliano Cala
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapies
H?©l?¨ne Tillaut, Adeline Degr?©mont, Sandrine Kerbrat, Jonathan Roux, Emmanuelle Le Page, Christelle Mainguy, Sol?¨ne Duros, Elisabeth Polard, Emmanu
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial
Bianca Weinstock-Guttman, Robert Bermel, Gary Cutter, Mark S Freedman, Thomas P Leist, Xiaoye Ma, Deidre Kile, Bruno Musch, Anthony T Reder, Jerry S W
Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results
Ralf Gold, Douglas L Arnold, Amit Bar-Or, Robert J Fox, Ludwig Kappos, Oksana Mokliatchouk, Xiaotong Jiang, Jennifer Lyons, Shivani Kapadia, Catherine
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment
Jeffrey A Cohen, Michelle H Cameron, Myla D Goldman, Andrew D Goodman, Aaron E Miller, Anne Rollins*, Lily Llorens*, Rajiv Patni*, Robert Elfont*, Ree
The effect of national disease-modifying therapy subsidy policy on long-term disability outcomes in people with multiple sclerosis
Suzi B Claflin, Julie A Campbell, Deborah F Mason, Tomas Kalincik, Steve Simpson-Yap, Richard Norman, Helmut Butzkueven, William M Carroll, Andrew J P
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Alasdair J Coles*, Joanne L Jones*, Patrick Vermersch, Anthony Traboulsee, Ann D Bass, Aaron Boster, Andrew Chan, Giancarlo Comi, ?“scar Fern??ndez, G
